Huge sales leaps for AbbVie's Humira have been powering revenue forecast beats for the company in recent quarters. But this time, international sales of the drug took a hit, leading the Illinois pharma to fall short of analysts' top-line expectations.
Industry watchers expect biosimilars for AbbVie's Humira to be the most successful copycat biologics launched in the U.S. and Europe, and that's something Merck and Samsung are trying to get in on.
South Korea-based Samsung Bioepis is ready to head to regulators with a biosimilar of AbbVie's Humira (adalimumab) after successfully completing Phase III trials on its candidate now dubbed SB5. The company says SB5 met its primary endpoint and showed equivalence to the original version in patients with moderate to severe rheumatoid arthritis who did not respond to methotrexate therapy.
With biosimilars makers eager to grab a piece of Humira's $12.5 billion-plus revenue, copies of AbbVie's blockbuster are on their way. What analysts disagree on, though, is when they'll arrive and how long it'll take them to make their presence known--and a pair of UBS analysts, for one, thinks the Illinois pharma has some marketing maneuvers up its sleeve to minimize their impact.
Here's something AbbVie doesn't want to hear: Industry watchers expect biosimilars for its top moneymaker Humira to be the most successful copycat biologics launched in the U.S. and Europe.
AbbVie is working to lessen its reliance on blockbuster Humira, which is already facing biosimilar competition in India. But it's also working to broaden the drug's label, and on that front, it got a boost from the FDA on Friday.
AbbVie's Humira is riding high, as usual--but according to the company's execs, in the U.S., it's riding higher than ever. The company's going to need to apply that market-share magic to new launch Viekira Pak, which fell short of analysts' Q1 sales estimates. But that effort is already going better than investors may think, management says.
AbbVie's working toward solutions to protect its top line against Humira's inevitable decline. For now, though, its workhorse is still getting the job done, and it delivered yet another double-digit leap in Q1 to help the company beat expectations.
It's no secret that AbbVie's sales are in for a shock once generic competition starts eating away at behemoth Humira. But worry not, investors: The company will be able to shield its EPS from the hit when the time comes, one analyst believes.
Pharma analysts have different opinions on how much branded drugmakers will feel the heat from biosimilars--and when they'll feel it. But according to one Citi analyst, they're all underestimating the impact on AbbVie's top dog.